Over the last three months, 9 analysts shared their evaluations of Travere Therapeutics TVTX, revealing numerous outlooks from bullish to bearish.
The next desk summarizes their current rankings, shedding gentle on the altering sentiments throughout the previous 30 days and evaluating them to the previous months.
| Bullish | Considerably Bullish | Detached | Considerably Bearish | Bearish | |
|---|---|---|---|---|---|
| Complete Scores | 5 | 3 | 1 | 0 | 0 |
| Final 30D | 1 | 0 | 0 | 0 | 0 |
| 1M In the past | 3 | 1 | 1 | 0 | 0 |
| 2M In the past | 0 | 2 | 0 | 0 | 0 |
| 3M In the past | 1 | 0 | 0 | 0 | 0 |
The 12-month value targets, analyzed by analysts, provide insights with a median goal of $37.89, a excessive estimate of $47.00, and a low estimate of $25.00. This present common displays a rise of 9.04% from the earlier common value goal of $34.75.
Diving into Analyst Scores: An In-Depth Exploration
A complete examination of how monetary consultants understand Travere Therapeutics is derived from current analyst actions. The next is an in depth abstract of key analysts, their current evaluations, and changes to rankings and value targets.
| Analyst | Analyst Agency | Motion Taken | Score | Present Worth Goal | Prior Worth Goal |
|---|---|---|---|---|---|
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Purchase | $47.00 | $47.00 |
| Alex Thompson | Stifel | Raises | Maintain | $25.00 | $20.00 |
| Mohit Bansal | Wells Fargo | Raises | Obese | $35.00 | $27.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Purchase | $47.00 | $47.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Purchase | $47.00 | $47.00 |
| Joseph Pantginis | HC Wainwright & Co. | Raises | Purchase | $47.00 | $30.00 |
| Greg Harrison | Scotiabank | Raises | Sector Outperform | $31.00 | $30.00 |
| Laura Chico | Wedbush | Raises | Outperform | $32.00 | $30.00 |
| Joseph Pantginis | HC Wainwright & Co. | Pronounces | Purchase | $30.00 | – |
Key Insights:
- Motion Taken: Responding to altering market dynamics and firm efficiency, analysts replace their suggestions. Whether or not they ‘Preserve’, ‘Increase’, or ‘Decrease’ their stance, it signifies their response to current developments associated to Travere Therapeutics. This provides perception into analysts’ views on the present state of the corporate.
- Score: Gaining insights, analysts present qualitative assessments, starting from ‘Outperform’ to ‘Underperform’. These rankings mirror expectations for the relative efficiency of Travere Therapeutics in comparison with the broader market.
- Worth Targets: Gaining insights, analysts present estimates for the long run worth of Travere Therapeutics’s inventory. This comparability reveals tendencies in analysts’ expectations over time.
Navigating by means of these analyst evaluations alongside different monetary indicators can contribute to a holistic understanding of Travere Therapeutics’s market standing. Keep knowledgeable and make data-driven selections with our Scores Desk.
Keep updated on Travere Therapeutics analyst rankings.
All You Must Know About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical firm. The corporate is concentrated on figuring out, growing and delivering life-changing therapies to individuals dwelling with uncommon kidney, liver, and metabolic ailments. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage improvement for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney problems that usually trigger end-stage kidney illness.
Monetary Milestones: Travere Therapeutics’s Journey
Market Capitalization Evaluation: Positioned beneath business benchmarks, the corporate’s market capitalization faces constraints in dimension. This may very well be influenced by components reminiscent of development expectations or operational capability.
Income Development: Travere Therapeutics displayed optimistic leads to 3M. As of 30 June, 2025, the corporate achieved a strong income development fee of roughly 111.49%. This means a notable improve within the firm’s top-line earnings. As in comparison with rivals, the corporate surpassed expectations with a development fee greater than the common amongst friends within the Well being Care sector.
Web Margin: Travere Therapeutics’s web margin surpasses business requirements, highlighting the corporate’s distinctive monetary efficiency. With a powerful -11.14% web margin, the corporate successfully manages prices and achieves robust profitability.
Return on Fairness (ROE): The corporate’s ROE is beneath business benchmarks, signaling potential difficulties in effectively utilizing fairness capital. With an ROE of -38.91%, the corporate might have to deal with challenges in producing passable returns for shareholders.
Return on Belongings (ROA): The corporate’s ROA is a standout performer, exceeding business averages. With a powerful ROA of -2.31%, the corporate showcases efficient utilization of property.
Debt Administration: Travere Therapeutics’s debt-to-equity ratio stands notably greater than the business common, reaching 12.2. This means a heavier reliance on borrowed funds, elevating considerations about monetary leverage.
What Are Analyst Scores?
Consultants in banking and monetary methods, analysts focus on reporting for particular shares or outlined sectors. Their complete analysis includes attending firm convention calls and conferences, analyzing monetary statements, and interesting with insiders to generate what are referred to as analyst rankings for shares. Usually, analysts assess and fee every inventory as soon as per quarter.
Past their customary evaluations, some analysts contribute predictions for metrics like development estimates, earnings, and income, furnishing buyers with further steerage. Customers of analyst rankings needs to be aware that this specialised recommendation is formed by human views and could also be topic to variability.
Breaking: Wall Road’s Subsequent Large Mover
Benzinga’s #1 analyst simply recognized a inventory poised for explosive development. This under-the-radar firm may surge 200%+ as main market shifts unfold. Click on right here for pressing particulars.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
